Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23774990 | 0.80 | SMN1; SMN2 (0.39) | CA2PTPN1ALDH1A1 | |
| SCHEMBL17291956 | 0.74 | PTGDR2 (0.35) | PTPN1ALDH1A1 | |
| SCHEMBL18077844 | 0.74 | PTPN1 (0.32) | PTPN1ALDH1A1 | |
| SCHEMBL17292081 | 0.74 | PTPN1 (0.35) | PTPN1ALDH1A1 | |
| SCHEMBL16259713 | 0.72 | CA2 (0.41) | CA1CA2ALDH1A1 | |
| SCHEMBL8807107 | 0.70 | ALDH1A1 (0.39) | CA1CA2PTPN1ALDH1A1 | |
| SCHEMBL17298431 | 0.69 | CA2 (0.61) | CA1CA2ALDH1A1 | |
| SCHEMBL28734927 | 0.68 | CA2 (0.46) | CA1CA2ALDH1A1 | |
| SCHEMBL5086986 | 0.68 | CYP2D6 (0.38) | CA2ALDH1A1 | |
| SCHEMBL26624872 | 0.68 | CYP2D6 (0.38) | CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458104-B2 | Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγ | PHENEX PHARMACEUTICALS AG (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150344423-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | PHENEX PHARMACEUTICALS AG (DE) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344423-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | RORA, RORB, RORC | CA1 700/4885CA2 626/4885PTPN1 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.